CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc. (CV) announced that its AI Highlights reading tool for the CapsoCam Plus system received U.S. Food and Drug Administration clearance on September 25, 2026. The tool is designed to support physicians reviewing small bowel capsule endoscopy studies from adult and pediatric patients over two years of age when the study was performed due to suspected small bowel bleeding.
AI Highlights analyzes capsule video frames, marks images containing suspected abnormal lesions, and prioritizes them for physician review. It is designed to reduce the time taken to review capsule endoscopy images. The feature integrates with CapsoView software and supports connected CapsoCloud workflows, depending on workflow configuration. It is intended for trained healthcare professionals and is not intended to replace gastroenterologists’ diagnostic interpretation or, where applicable, histopathological sampling.
The Harari 2010 Children Remainder Trust - DAH purchased 878,735 shares of CapsoVision, Inc. common stock, and The Harari Descendant's Trust-2012 purchased 878,734 shares, each at $5.6900 per share on September 18, 2026. Eliyahou Harari, identified as a 10% owner, and his wife are trustees of both trusts. No Rule 10b5-1 plan is reported for the purchases.
CapsoVision, Inc. (CV) ten percent owner Shen Ching Hang transferred 3,991,606 common shares on April 17, 2026, from direct ownership to indirect ownership through Star One Global Capital Limited, an entity he wholly owns and controls. The transfer involved no cash or other consideration; his reported direct holdings fell to 0 shares, while the reported indirect position through Star One was 6,400,527 shares after the transfer. The transfer is described as a change in the form of beneficial ownership exempt under Rule 16a-13, and Shen retains sole voting and investment power over the shares held by Star One.
For CapsoVision, Inc. (CV), a Form 4/A amendment corrects the reported beneficial ownership total following a purchase on September 15, 2026. The transaction was an indirect purchase of 878,734 common shares at $5.69 per share through Star One Global Capital Limited; Shen Ching Hang is identified as a ten-percent owner. The corrected post-transaction total is 7,279,261 shares. No Rule 10b5-1 plan is reported.
CapsoVision, Inc (CV) had a Form 4 filed reporting that major shareholder Ching Hang Shen, a ten percent owner, purchased 878,734 shares of common stock on September 15, 2026 at $5.69 per share.
The shares are held indirectly through Star One Global Capital Limited, bringing this indirect position to 2,926,655 shares after the transaction. No Rule 10b5-1 trading plan is reported for this purchase.
CapsoVision, Inc. (CV) entered into a securities purchase agreement on September 17, 2026 for a registered direct offering of 3,163,444 shares of common stock at $5.69 per share, a discount of about 5% to the last reported Nasdaq Capital Market sale price on September 16, 2026.
The offering, completed without an underwriter or placement agent, is expected to close on or about September 18, 2026, subject to customary conditions. All purchasers are existing stockholders: Star One Global Capital Limited will purchase 878,734 shares for approximately $5.0 million, Eliyahou Harari will purchase 1,757,469 shares for approximately $10.0 million, and another stockholder will purchase 527,241 shares for approximately $3.0 million.
Gross proceeds to CapsoVision are expected to be approximately $18 million, before expenses. The board of directors approved the transaction, and the audit committee reviewed and approved the related person transactions. CapsoVision plans to use net proceeds for general corporate purposes, including sales and marketing, research and development, general and administrative activities, and working capital. The shares are being issued under an effective Form S-3 registration statement and a prospectus supplement dated September 17, 2026.
CapsoVision, Inc. (CV) is conducting a primary offering of 3,163,444 shares of common stock at $5.69 per share to existing investors under a shelf registration, for gross proceeds of about $18.0 million and estimated net proceeds of about $17.8 million after expenses. The price reflects a discount of approximately 5% to the $5.99 last reported sale price on The Nasdaq Capital Market on September 16, 2026, and no underwriter or placement agent is involved, so no underwriting discounts or commissions are being paid.
Shares outstanding will increase from 50,032,148 as of June 30, 2026 to 53,195,592 after the offering, excluding warrants, options, RSUs, plan reserves and recent ATM issuances. The company plans to use the proceeds for general corporate purposes, including sales and marketing, research and development, general and administrative expenses, and working capital, with interim investment in money market funds.
CapsoVision is a commercial-stage medical technology company focused on GI-tract capsule endoscopy, deriving most of its revenue from its FDA-cleared CapsoCam Plus capsule. Revenue from CapsoCam Plus was approximately $6.4 million for the six months ended June 30, 2026 versus $6.1 million a year earlier, and $13.6 million for 2025 versus $11.8 million for 2024. The company highlights pipeline efforts including AI-assisted CapsoCam Plus, a second-generation CapsoCam Colon capsule, and early-stage pancreatic cancer and esophageal indications, while cautioning that regulatory clearances and clinical results are uncertain.
CapsoVision, Inc. (CV) has established an at-the-market equity offering program under a Form S-3 shelf, allowing it to sell up to $100,000,000 of common stock from time to time through Cantor Fitzgerald & Co. as sales agent or principal. Sales will be made on The Nasdaq Capital Market or other permitted methods deemed an “at the market offering” under Rule 415(a)(4).
Cantor will use commercially reasonable efforts and receive up to 3.0% of aggregate gross proceeds as commissions, and will be deemed an underwriter. Assuming an illustrative price of $6.86 per share (the August 12, 2026 last sale price) and full utilization, CapsoVision would sell approximately 14,577,259 shares, resulting in up to 64,609,407 shares outstanding. Net tangible book value would increase from $0.26 to $1.70 per share, implying dilution of $5.16 per share to new investors at that price.
The company intends to use any net proceeds for general corporate purposes, including sales and marketing, research and development, general and administrative expenses, and working capital, with interim investment in money market funds. The filing highlights that investing involves a high degree of risk, including potential volatility, future capital needs, and possible additional dilution from outstanding warrants, options, restricted stock units, and future equity issuances.
CapsoVision, Inc. entered into a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. for an at-the-market offering program. Under this arrangement, CapsoVision may sell, at its sole discretion, shares of its common stock having an aggregate offering price of up to $100,000,000 through or to Cantor as sales agent or principal. The shares will be issued pursuant to a Registration Statement on Form S-3 (File No. 333-298315), which includes an at-the-market offering prospectus supplement filed on August 13, 2026. O’Melveny & Myers LLP provided a legal opinion on the validity of the shares, filed as Exhibit 5.1.